title: Metabolic vulnerability in melanoma: a ME2 (me too) story.
abstract: Metabolic reprograming is a hallmark of cancer and might represent an Achilles' heel in cancer cells. The study by Chang et al. in this issue highlights a critical role of mitochondrial malic enzyme 2 (ME2) in melanoma progression. Targeting ME2 could be an effective approach to inhibit melanoma cell proliferation and tumor growth.
authors: Department of Dermatology, Cutaneous Biology Research Center, Harvard Medical School, Massachusetts General Hospital, Boston, Massachusetts, USA.
authors: Bin
authors: B
authors: Zheng
authors: Department of Dermatology, Cutaneous Biology Research Center, Harvard Medical School, Massachusetts General Hospital, Boston, Massachusetts, USA. Electronic address: dfisher3@mgh.harvard.edu.
authors: David E
authors: DE
authors: Fisher
mesh_terms: D000818:Animals; D014408:Biomarkers, Tumor / Q000378:metabolism*; D018450:Disease Progression; D005260:Female; D006801:Humans; D008291:Malate Dehydrogenase / Q000378:metabolism*; D008545:Melanoma / Q000378:metabolism*; D008928:Mitochondria / Q000201:enzymology*; D009361:Neoplasm Invasiveness / Q000473:pathology*; D012878:Skin Neoplasms / Q000378:metabolism*
chemical_list: D014408:Biomarkers, Tumor; D008291:Malate Dehydrogenase; C495394:malic enzyme 2; human